The 3 Most Undervalued Dividend Stocks With Growth Potential to Buy Now: August 2023
Investors could be undergoing a flight to safety to dividend stocks. The reasoning is simple.
Covid booster jabs may go on sale in the UK for the first time
UK health officials have approved the private sale of Covid booster shots, marking a significant shift in approach to vaccine distribution. Previously, since the rollout began in December 2020, Cov...
Pfizer's updated COVID shot effective against 'Eris' variant in mice study
Pfizer Inc said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the "Eris" subvariant in a study conducted on mice.
Pfizer Stock: The Right Time To Buy Now (Technical Analysis)
Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of their leading drugs. Despite these challenges, Pfizer's resilience is highlighted by a robust divi...
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.
Pfizer (PFE) Seems Well-Poised for Long-Term Growth: Here's How
Though Pfizer's (PFE) revenues from COVID products are declining sharply, it is set to launch some key non-COVID products in 2023, which can drive long-term sales and profit growth.
Here's Why Pfizer's High-Yield Dividend Could Be Even Safer Than You Might Think
Pfizer's revenue and earnings are falling, and the company faces a patent cliff. However, a wave of new product launches and business development deals should help ensure Pfizer's dividend remains ...
Pfizer gets FDA accelerated approval for multiple myeloma treatment
A Pfizer Inc. PFE, +0.52% treatment for relapsed or refractory multiple myeloma has received accelerated approval from the U.S. Food and Drug Administration, the pharmaceutical company said Monday....
US FDA approves Pfizer's blood cancer therapy
The U.S. Food and Drug Administration on Monday granted accelerated approval to Pfizer's therapy for treating patients with a type of blood cancer that is difficult to treat, the company said.
2 High-Yield Dividend Stocks That Could Be Incredible Bargains
High-yield dividend stocks can be powerful capital appreciation vehicles. Pfizer and AT&T stand out as two of the most compelling buys within this group right now.
Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave
On August 1, Pfizer released its financial report for the second quarter of 2023, which showed mixed results. Pfizer's revenue for the second quarter of 2023 was $18.28 billion, down 24.7% from the...
Does Pfizer Stock Belong in a Dividend Portfolio?
Pfizer's non-COVID business grew in the second quarter. It has numerous potential blockbusters in the works.
Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?
Pfizer's revenue in Q2 fell by 52% as demand for its COVID products nosedived. The company's earnings are just a fraction of what Pfizer generated a year ago.
3 Massively Undervalued Blue-Chip Stocks for High Total Returns
It's worth noting that blue-chip stocks go through their own bull and bear phase. Nvidia (NASDAQ: NVDA ) was under-performing until October 2022.
Related Companies